SEC Form 4 · accession 0001185185-18-001605
IGC Pharma, Inc. · IGC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ram Mukunda
Officer — Exec. Chairman & CEO · Director · 10% Owner
Period of report
Aug 14, 2018
Accepted (ET)
Aug 29, 2018 · 7:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326205
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Aug 14, 2018 | G | 160,000 | $0.37 | D | 1,999,760 | D | |
| Common stock | Aug 28, 2018 | S | 125,000 | $1.328 | D | 1,874,760 | D | |
| Common stockF1 | Aug 28, 2018 | A | 400,000 | $0.00 | A | 2,274,760 | D | |
| Common stockF2 | Aug 22, 2018 | S | 50,000 | $0.5021 | D | 410,189 | I | By Spouse |
| Common stockF2 | Aug 24, 2018 | S | 25,000 | $0.6397 | D | 385,189 | I | By Spouse |
| Common stockF1,F2 | Aug 28, 2018 | A | 107,228 | $0.00 | A | 492,417 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of Common Stock awarded pursuant to the Issuer's 2018 Omnibus Incentive Plan and the shareholder-approved Special Grant.
- F2Represents shares held directly by CEO's spouse.